Elutia is a commercial-stage regenerative medicine company focused on creating the differentiated products and improving outcomes in patients undergoing surgery. In device protection, Co. sells the biological envelope that forms a natural vascularized pocket for holding implanted electronic devices. In cardiovascular, Co. sells its Small intestinal submucosa extracellular matrix for use as an intracardiac and vascular patch. In orthobiologics, Co. has a proprietary processing technology for manufacturing a portfolio of bone regenerative products. In women's health, Co. has a patented cell removal technology that produces undamaged extracellular dermal matrices with handling. The ELUT average annual return since 2020 is shown above.
The Average Annual Return on the ELUT average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ELUT average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ELUT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|